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A B S T R A C T
The therapeutic potential of small nucleic acids such as small interfering RNA (siRNA) to
treat lung diseases has been successfully demonstrated in many in vivo studies. A major
barrier to their clinical application is the lack of a safe and efficient inhaled formulation.
In this study, spray freeze drying was employed to prepare dry powder of small nucleic acids.
Mannitol and herring sperm DNA were used as bulking agent and model of small nucleic
acid therapeutics, respectively. Formulations containing different solute concentration and
DNA concentration were produced.The scanning electron microscope (SEM) images showed
that the porosity of the particles increased as the solute concentration decreased. Powders
prepared with solute concentration of 5% w/v were found to maintain a balance between
porosity and robustness. Increasing concentration of DNA improved the aerosol perfor-
mance of the formulation.The dry powder formulation containing 2% w/w DNA had amedian
diameter of 12.5 µm, and the aerosol performance study using next generation impactor
(NGI) showed an emitted fraction (EF) and fine particle fraction (FPF) of 91% and 28% re-
spectively. This formulation (5% w/v solute concentration and 2% w/w nucleic acid) was
adopted subsequently to produce siRNA powder. The gel retardation and liquid chroma-
tography assays showed that the siRNA remained intact after spray freeze drying even in
the absence of delivery vector. The siRNA powder formulation exhibited a high EF of 92.4%
and a modest FPF of around 20%. Further exploration of this technology to optimise inhaled
siRNA powder formulation is warranted.
© 2018 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
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1. Introduction
Small nucleic acid molecules such as small interfering RNA
(siRNA) have a huge therapeutic potential to treat respiratory
diseases including asthma, influenza, respiratory syncytial virus
(RSV) infection and tuberculosis. [1–4] siRNA works by inhib-
iting specific gene expression through RNA interference (RNAi),
which is a Nobel Prize-winning discovery [5]. One of the bar-
riers to the clinical application of siRNA therapeutics is delivery.
Pulmonary delivery of siRNA could increase drug concentra-
tion at the site of action and minimize systemic exposure. It
can also avoid serum interaction and nuclease degradation that
occurs in the bloodstream. One interesting observation of pul-
monary siRNA delivery is that naked siRNA (without the use
of delivery vector) couldmediate gene-silencing effect in animal
models and clinical trials [6–10]. It has been suggested that the
presence of pulmonary surfactants in the airway could act as
‘natural carrier’ that facilitate the cellular uptake of siRNA.While
the cellular uptake mechanism of naked siRNA remains to be
elucidated, it is highly desirable to develop an inhaled formu-
lation of siRNA that can maximize pulmonary delivery
efficiency.
Dry powder formulation has several advantages over liquid
aerosol formulation when it comes to macromolecules such
as nucleic acids. Dry powder formulation offers better stabil-
ity. It minimizes the exposure to high shear stress (during
nebulisation) and avoids the compatibility issues with propel-
lants (in metered dose inhaler (MDI)). Several particle
engineering methods have been considered to be suitable for
preparing inhaled powder formulation of nucleic acids, namely
spray drying, spray freeze drying and supercritical fluid tech-
nology [11]. It is the interest of this paper to explore the potential
of spray freeze drying for preparing inhaled powder formula-
tion of siRNA.
Spray freeze drying is a multi-step process that involves the
spray freezing step and freeze drying step.The potential of spray
freeze drying is being explored in the food industry and the
pharmaceutical industry [12,13]. During the spray freezing step,
the drug dissolved or suspended in liquid is atomized into fine
droplets which are frozen instantaneously by a cryogenic fluid,
usually liquid nitrogen. Subsequently, the frozen particles are
subjected to freeze drying, in which the solvents are sub-
limed at low temperature and pressure, leading to the formation
of dried porous particles.The porous particles produced by spray
freeze drying have made this technology an attractive method
for preparing inhaled powder. Porous particles with large physi-
cal size and low density exhibit small aerodynamic size, which
can promote high flowability. The small contact surface area
to volume ratio leads to low cohesion force between par-
ticles, thereby facilitates dispersibility in air. In addition, porous
particles have high specific surface area, thereby enhancing dis-
solution rate in the lungs. Spray freeze drying also holds several
advantages over spray drying and supercritical fluid drying,
which are also investigated in the preparation of inhaled powder
formulation of small nucleic acid [14–16]. In spray drying, ma-
terials are inevitably exposed to elevated temperature, which
may lead to significant loss of biological activity. In addition,
the recovery yield is relatively low. In supercritical fluid drying,
the size and morphology of powders cannot be easily con-
trolled, rendering the optimisation process extremely difficult.
Spray freeze drying can avoid these problems associated with
these two drying technologies [11].
Previously, our group has demonstrated the use of spray
freeze drying technology to produce dry powder of DNA com-
plexes that are suitable for inhalation [17]. To the best of our
knowledge, using spray freeze drying technology to produce
siRNA, either with delivery vector or in its ‘naked’ form, has
not been reported. This study aimed to investigate the use of
spray freeze drying to prepare inhaled dry powder formula-
tion of siRNA, with mannitol employed as a bulking agent.
Initially, herring sperm DNA (<50 base pairs), which has a size
comparable to that of siRNA (21 base pairs), was used as model
nucleic acids to examine how the solute concentrations and
nucleic acids concentrations affect the physicochemical prop-
erties and aerosol performance of the spray freeze dried powder.
Subsequently, the siRNA powder was prepared with the opti-
mized formulation. The integrity of siRNA, the particle size
distribution, morphology and the aerosol performance of the
siRNA formulation were evaluated.
2. Materials and methods
2.1. Materials
Mannitol (Pearlitol 160C) was obtained from Roquette (Lestrem,
France). siRNA targeting interleukin 10 (IL-10) (antisense strand:
5’-CAUUAAGGAGUCGGUUAGCUU-3’) was purchased from In-
tegrated DNA Technologies Pte. Ltd. (Singapore) as custom-
made RNA duplexes. Herring sperm DNA, other reagents and
solvents were purchased from Sigma (Poole, UK) and were of
analytical grade or better. DNA was purified by ethanol pre-
cipitation before use.
2.2. Spray freeze drying of nucleic acid formulations
Table 1 shows the different formulations of mannitol/DNA or
mannitol/siRNA solutions that were prepared in ultrapure water
at solute concentrations ranging from 1% to 7.5% w/v.The spray
freeze drying process is illustrated in Fig. 1.The solutions (5 ml)
were transferred into a syringe and fed to an ultrasonic at-
omiser nozzle (130K50ST, Sonaer®, Farmingdale, NY, USA)
operating at 130 kHz powered by digital ultrasonic generator
for atomisers (Sonaer®, NY, USA) at a controlled rate of 2 ml/
min via a syringe pump. The atomised liquid droplets were
collected in liquid nitrogen to allow instant freezing.The frozen
particles were lyophilised.The samples were kept under vacuum
(chamber pressure below 0.133 mBar) at −25 °C for 40 h, fol-
lowed by secondary drying at 20 °C for 8 h.The dried powders
were collected and stored in dessicator with silica gel at ambient
temperature until further analysis. The production yield was
calculated by dividing the total mass of powder collected by
the initial mass input.
2.3. Particle size distribution
The particle size distribution of the spray freeze dried powder
was measured by laser diffractometer operated with the Micro
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Liquid Module (LS 13 320; Beckman Coulter, Pasadena, USA).
Approximately 5 mg of powders were suspended in 7.5 ml of
chloroform. The suspended particles were de-aggregated by
ultra-sonication for approximately 10 s. Immediately after de-
aggregation, the suspension was added to the sample
compartment dropwise until the optimal obscuration (8%–
12%) was achieved. The stirrer was switched on to minimize
re-aggregation.The refractive index of mannitol was set at 1.544,
and the attenuation coefficient (imaginary refractive index) was
set at 0.1. The median (D50), the tenth (D10) and the ninetieth
(D90) percentile of the volumetric diameter were reported.The
width of the size distribution was expressed in terms of the
span: (D90–D10)/ D50. The particle size of each formulation was
measured in triplicates.
2.4. Morphology study
The morphology of the spray freeze dried powder was ob-
served by field emission scanning electron microscopy (Hitachi
S-3400N, Tokyo, Japan) at 10 kV. The powders were sprinkled
onto carbon stick tape that was mounted on SEM stubs. Excess
powders were removed by blowing with clean compressed air.
The powders were sputter coated with a sputter coater (Bal-
tec SCD 005 Sputter Coater, Bal-Tec GmbH, Schalksmühle,
Germany) with approximately 11 nm gold-palladium alloy in
two cycles (60 s each) to avoid overheating.
2.5. Aerosol performance
The aerosol performance of the spray freeze dried powder was
evaluated by a Next Generation Impactor (NGI; Copley, Not-
tingham, United Kingdom) in accordance to the British
Pharmacopoeia 2017 [18]. For each dispersion, approximately
4.0 ± 0.5 mg of powders were loaded in a size 3 hydroxypropyl
methylcellulose capsules (Capsugel,West Ryde, NSW, Austra-
lia), which were placed in a Breezhaler® (Novartis
Pharmaceuticals, Hong Kong). The dispersion rate and dura-
tion were 100 l/min and 2.4 s, respectively. Prior to each
dispersion, a thin layer of silicon grease (Dry Film Silicone Lu-
bricant, LPS Laboratories, GA, USA) was coated onto the
impactor stages to minimize particle bounce. After disper-
sion, the powders deposited on the inhaler and NGI stages were
collected by rinsing with 4 ml of ultrapure water. For each
powder formulation, powder dispersions were performed in trip-
licates. The emitted fraction (EF) was defined as the mass of
powders (as calculated with the assayed mannitol) that exited
Table 1 – Different spray freeze dried formulation containing mannitol and nucleic acids (DNA or siRNA).
Formulation Solute
concentration (%)
Percentage by mass (%) Mannitol to
DNA (wt. ratio)
Nucleic acid Mannitol
1-D-1.00 1 1 (DNA) 99 99:1
2.5-D-1.00 2.5 1 (DNA) 99 99:1
5-D-1.00 5 1 (DNA) 99 99:1
7.5-D-1.00 7.5 1 (DNA) 99 99:1
5-D-0.25 5 0.25 (DNA) 99.75 399:1
5-D-0.50 5 0.5 (DNA) 99.5 199:1
5-D-0.75 5 0.75 (DNA) 99.25 132:1
5-D-1.50 5 1.5 (DNA) 98.5 66:1
5-D-2.00 5 2 (DNA) 98 49:1
a5-S-2.00 5 2 (siRNA) 98 49:1
a The formulation of siRNA was established after the characterisation of the DNA formulations.
Fig. 1 – Schematic diagram of spray freeze drying process. The feed liquid containing mannitol and nucleic acids is
atomised through the atomizer nozzle into fine droplets. The feeding rate is controlled by the syringe pump. A conducting
collector containing liquid nitrogen was immersed in an insulating container which is half-filled with liquid nitrogen. The
droplets are instantaneously frozen when they are in contact with the liquid nitrogen in the collector. The frozen particles
are then subjected to freeze drying in which ice crystals are sublimed to vapour at low temperature and pressure, leading to
the formation of dried porous particles.
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the inhaler with respect to the recovered dose. The fine par-
ticle fraction (FPF) was defined as the mass of powders with
aerodynamic diameter < 5.0 µm with respect to the recov-
ered dose.
2.6. High performance liquid chromatography (HPLC)
Quantification of mannitol in the dispersed samples in NGI was
performed using HPLC (Agilent 1260 Infinity; Agilent Technolo-
gies, Santa Clara, USA) with a refractive index detector (G1362A;
Agilent Technologies). The injection volume was 50 µl and the
samples were passed through an ion-exchange ligand-exchange
column (Agilent Hi-Plex Ca, 7.7 mm × 300 mm, 8 µm; Agilent
Technologies) maintained at 75 °C with ultrapure water running
at 0.6 ml/min as the mobile phase.The actual mass of powder
deposited in various stages of the NGI was calculated based
on the formulation compositions. For siRNA-containing samples,
the integrity of siRNA was studied by HPLC using column for
ion-pair reversed-phase separation (AdvanceBio Oligonucle-
otide, 2.1 mm × 50 mm, 2.7 µm; Agilent Technologies) [19]. The
siRNA powder was dissolved in water. Unformulated siRNA and
the sense strand of the siRNA were included as controls. Mobile
phase A consisted of 100 mM triethylamine acetate (TEAA) at
pH 7; mobile phase B consisted of 20% acetonitrile in mobile
phase A.The column temperature was maintained at 30 °C.The
injection volume was 5 µl with a flow rate of 0.3 ml/min. Gra-
dient was 35% to 50%mobile phase B over 10 min.A photodiode
array detector was used for signal detection at 260 nm.
2.7. Gel retardation assay
To examine the integrity of siRNA following spray freeze drying,
the powders were reconstituted inTris-borate-EDTA (TBE) buffer
and resolved by gel retardation assay. Unformulated siRNA and
the sense strand of the siRNA were included as controls.
Samples containing 1 µg of nucleic acid in a final volume of
10 µl were loaded into a 15% (w/v) native polyacrylamide gel.
Gel electrophoresis was run at 60 V for 3 h in TBE buffer (Mini-
PROTEAN Tetra Cell, Bio-Rad Laboratories, California, USA).
Nucleic acids in the gel were stained with GelRed™ Nucleic
Acid Gel Stain (Biotium, Hayward, CA, USA) in TBE buffer for
30min. Subsequently, the gel was visualized and captured under
UV illumination (G:Box XR5; Syngene, Cambridge, United
Kingdom).
2.8. Statistical analysis
Statistical analyses were performed by GraphPad Prism sta-
tistics software (Version 6.0b). The data were analysed by one-
way ANOVA followed byTukey’s post-hoc test. Differences were
considered as statistically significant at P < 0.05.
3. Results and discussion
3.1. Physical properties of DNA powder formulations
To allow efficient lung deposition, an inhaled dry powder for-
mulation must exhibit good dispersibility.The optimal particle
size for lung deposition is reported to be between 1–5 µm aero-
dynamic diameter, which is affected by the geometric diameter
as well as the density of the particles [20]. Particles with a geo-
metric diameter of 1–5 µm usually have poor flowability and
dispersibility due to the strong cohesion force. On the other
hand, porous particles with large geometric size tend to have
small aerodynamic size because of the low density.These types
of particles are desirable for inhalation due to the good
flowability and dispersibility [21]. Spray freeze drying is one of
the particle engineering technologies to produce porous powder.
By altering the solute concentration of the feed solution for
spray freeze drying, the porosity of the particles could be
controlled.
Production yield is an important factor to consider in pre-
paring powder formulation of nucleic acids which are more
expensive than the small drug molecules. Table 2 shows the
production yield of the spray freeze dried formulations, and
all formulations had a satisfactory yield, with at least 83% w/w
yield obtained. Most of the formulations had a yield above 90%
w/w. The effect of solute concentration on powder properties
was first examined. A series of DNA formulations was pre-
pared at various solute concentration from 1% to 7.5%w/v,while
Table 2 – The production yield and particle size distribution (measured by laser diffraction) of spray freeze dried
formulation. The volumetric diameter was presented as mean ± SD (n = 3).
Formulation Production
yield (% w/w)
Volumetric diameter ± SD
D10 (µm) D50 (µm) D90 (µm) Span
b1-D-1.00 83.70 1.89 ± 0.32 8.65 ± 0.85 16.78 ± 1.64 1.72 ± 0.04
2.5-D-1.00 93.76 3.12 ± 0.16 11.14 ± 0.48 21.87 ± 1.13 1.68 ± 0.04
a,b5-D-1.00 89.76 4.85 ± 0.20 12.58 ± 0.85 21.28 ± 1.97 1.29 ± 0.06
7.5-D-1.00 90.80 5.92 ± 1.27 11.98 ± 2.35 19.95 ± 4.45 1.17 ± 0.06
5-D-0.25 93.08 4.73 ± 0.30 12.83 ± 0.80 22.98 ± 1.48 1.42 ± 0.02
5-D-0.50 90.48 4.48 ± 0.09 11.54 ± 0.71 19.78 ± 1.30 1.32 ± 0.03
5-D-0.75 98.92 5.91 ± 1.85 14.89 ± 1.13 25.01 ± 1.26 1.29 ± 0.15
a5-D-1.00 89.76 4.85 ± 0.20 12.58 ± 0.85 21.28 ± 1.97 1.29 ± 0.06
5-D-1.50 90.00 3.21 ± 2.40 12.55 ± 3.53 21.08 ± 6.42 1.52 ± 0.10
5-D-2.00 90.92 1.42 ± 0.28 10.02 ± 1.80 17.89 ± 2.78 1.65 ± 0.05
5-S-2.00 92.93 3.71 ± 0.83 15.20 ± 2.99 26.35 ± 5.08 1.48 ± 0.08
a The same formulation is present twice in different series for easy comparison.
b There was a significant difference in D50 between these formulations (P < 0.05).
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the DNA concentration was kept at 1% w/w. As shown in
Table 2, the volumetric diameter of the particles was mea-
sured by laser diffraction.The median diameter of the particles
ranged from 8.7 µm to 12.6 µm. Formulation formed with 1%
w/v solute concentration was generally smaller than the rest
of the formulations in the same series. The median diameter
of 5-D-1.00 (5%w/v solute concentration) was significantly larger
than that of 1-D-100 (1% w/v solute concentration) (P < 0.05).
Fig. 2 shows the morphology of the particles examined by SEM.
Overall, the particles of different formulations were spherical
in shape. As expected, spray freeze drying of liquid with lower
solute concentration (1% and 2.5%) produced particles of higher
porosity, according to the SEM images, which is a qualitative
evaluation. As shown in Fig. 2A-D, these particles appeared to
be more fragile, as fragments were easily noticed in the images.
In addition, the low magnification images, Fig. 2B and 2D,
showed that the powders of these formulations were highly
aggregating. On the other hand, the particles produced with
higher solute concentration (5% and 7.5%), as demonstrated
in Fig. 2E-H, appeared as individual, discrete particles. The
particle size data from laser diffraction showed that the higher
the solute concentration, the lower the span value, indicat-
ing that the particle size distribution was more uniform as
solute concentration increased. It was obvious that the D10 value
of formulation with low solute concentration wasmuch smaller,
possibly due to the presence of the small fragmented par-
ticles and debris. Judging from the SEM images, the spray freeze
dried powders have to be prepared with at least 5% w/v solute
concentration to be considered as ‘robust’ enough as inhaled
formulations.
To examine the effect of DNA concentration in the formu-
lation, another series of spray freeze dried powders was
prepared, with the solute concentration kept at 5% w/v while
the DNA concentration varied from 0.25% to 2% w/w.As shown
in Table 2, the median diameter of the particles ranged from
10.0 µm to 14.9 µm, with no clear trend observed as the DNA
concentration varied. Fig. 3 shows the SEM images which reveal
that all the particles of this series appeared to be porous and
spherical. However, there was no obvious difference in poros-
ity between these formulations when observed by the SEM. It
is noted that SEM is not a quantitative method to measure par-
ticle porosity.Techniques such as gas adsorption and Brunauer,
Emmett and Teller (BET) analysis as well as mercury intru-
sion porosimetry could be employed to examine the porosity
of powders in the future.
3.2. Aerosol performance of DNA powder formulations
Next generation impactor (NGI) was employed to evaluate the
aerosol performance of the spray freeze dried powder formu-
lations. In particular, two parameters were closely examined
and compared between different formulations. The first one
is the emitted fraction (EF), which is shown in Fig. 4A and 4C.
EF indicates the fraction of powder that was successfully dis-
persed under the experiment condition (i.e., NGI operated at
100 l/min, equivalent to 4 kPa pressure drop) and exited the
inhaler (Breezhaler®, which is a low-resistance inhaler). All the
DNA formulations prepared in this study achieved a satisfac-
tory EF of over 90%, with no statistical significant difference
between all the formulations. The good dispersibility was at-
tributed to the porous structure and relatively large volumetric
size, which is the characteristic feature of powders formed by
spray freeze drying.
Once the powder successfully exited the inhaler upon in-
halation, it becomes available to the patients. However, only
particles that exhibited aerodynamic diameter between 1–5 µm
can reach the deep lung. Particles above that size range are likely
to be impacted at the back of the throat or in the upper re-
spiratory tract. The second important parameter is the fine
particle fraction (FPF), which is shown in Fig. 4B and 4D. FPF
indicates the fraction of powder with aerodynamic diam-
eter < 5 µmand could be deposited in the lower respiratory tract.
When the solute concentration increased, the FPF decreased
gradually. As shown in Fig. 4B, the formulation prepared with
Fig. 2 – Representative scanning electron microscopy (SEM) images of various spray freeze dried powder formulations with
1% w/w DNA concentration and varying solute concentrations: (A, B) 1% w/v solute (1-D-1.00); (C, D) 2.5% w/v solute (2.5-D-
1.00), (E, F) 5% w/v solute (5-D-1.00); (G, H) 7.5% w/v solute (7.5-D-1.00). Images A, C, E and G were taken at 1000 ×
magnification (scale bar = 50 µm); images B, D, F and H were taken at 100 × magnification (scale bar = 500 µm).
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7.5% w/v solute concentration exhibited a significantly lower
FPF (around 15%) than the rest of the formulations within the
same series, while there was no significant difference in FPF
between the others (FPF between 20%–25%). Since aerody-
namic diameter is influenced by particle density, as the solute
concentration increased, particles with lower porosity and
higher density were formed, thereby increasing aerodynamic
diameter and decreasing FPF.
Considering the morphology and aerosol performance of the
formulations, powders prepared with 5% w/v solute concen-
tration appeared to be the optimal formulation within the series
as they demonstrated porous but ‘robust’ structure, and a
modest FPF value. As shown in Fig. 4D, when the solute con-
centration of the formulations was maintained at 5% w/v and
the DNA concentration increased, there was a gradual in-
crease in FPF. The 2% w/w DNA formulation (the highest
concentration of DNA used in this study) performed signifi-
cantly better than the 0.25%, 0.5% and 1% w/w counterparts.
The FPF of the 2% w/w DNA formulation was close to 30%,
which was the highest value amongst all the DNA formula-
tions prepared in this study. One key advantage of using a higher
drug concentration in inhaled formulation is that the amount
of excipient and hence the powder mass are reduced, avoid-
ing repeated administration to achieve the same therapeutic
dose. The inter-stage distributions that are shown in Fig. S1
in the supplementary information suggested that the major-
ity of the powder was deposited on Stage 1 which has a cut-
off diameter of 6.12 µm.This indicates that the particles were
still too large for efficient lung deposition. Further increase in
DNA concentration could be explored to improve FPF. Alter-
natively, size reduction could be achieved by decreasing liquid
feed flow rate during atomisation or varying the frequency of
the ultrasonic nozzle [12,22]. For the interest of this paper, the
best performing formulation identified with herring sperm DNA
in the current study was employed in the subsequent siRNA
formulation study.
3.3. Spray freeze dried formulation of siRNA
Among the DNA formulations studied, the one prepared with
5% w/v solute concentration and 2% w/w DNA exhibited the
best aerosol performance. This formulation was therefore
adopted to prepare siRNA powder. The production yield was
over 90%, which was similar to DNA formulations. One of the
challenges in preparing dry powder of naked siRNA is to main-
tain the structural integrity of the unprotected nucleic acids.
During spray freeze drying, the materials are inevitably exposed
to high shear stress (during atomisation) and thermal stresses
(during freezing). These stresses could lead to strand separa-
tion and fragmentation of the unprotected siRNA [11], impairing
its biological activity.To evaluate the integrity of the siRNA after
spray freeze drying, gel retardation assay and liquid chroma-
tography assay were performed. In both assays, a single strand
RNA (the sense strand of siRNA) was included as control. The
Fig. 3 – Representative scanning electron microscopy (SEM) images of various spray freeze dried powder formulations with
5% w/v solute concentration and varying DNA concentrations: (A, B) 0.25% w/w DNA (5-D-0.25); (C, D) 0.5% w/w DNA (5-D-
0.50), (E, F) 0.75% w/w DNA (5-D-0.75; (G, H) 1% w/w DNA (5-D-1.00), (I, J) 1.5% w/w DNA (5-D-1.50); (K, L) 2% w/w DNA (5-D-
2.00). Images A, C, E, G, I and K were taken at 1000 × magnification (scale bar = 50 μm); images B, D, F, H, J and L were taken
at 100 × magnification (scale bar = 500 μm).
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gel image, as shown in Fig. 5A, revealed that the siRNA in the
powder formulation remained intact, with no observable deg-
radation upon drying. The results from the liquid
chromatography assay, which is shown in Fig. 5B, were con-
sistent with the gel retardation assay. The spectrum of siRNA
obtained from the reconstituted powder was almost identi-
cal to that obtained from the feed solution of the same
formulation prior to spray freeze drying.
Table 2 shows the particle size of the siRNA formulation
measured by laser diffraction. The median diameter of siRNA
powder was around 15.2 µm,which was considerably larger than
any of the DNA formulations. The morphology of the siRNA
formulation was also different from the DNA formulations. Fig. 6
shows the SEM images of the siRNA formulation. The siRNA
powder appeared to bemore porous and less spherical in shape.
High level of particle aggregation could be observed in image
that was taken at lower magnification.
The aerosol performance of siRNA powder was evaluated
by NGI, which is shown in Fig. 7. Similar to the DNA formu-
lations, the siRNA formulation had a satisfactory EF of over 90%.
The FPF was around 18% which was disappointing. The inter-
stage distribution profile showed that the majority of the siRNA
powders (~60%) was deposited in Stage 1. The relatively low
FPF of siRNA powder formulation (~18%) compared to its DNA
counterpart (~28%) could be explained by the larger particle
size, probably due to the stronger cohesion force and thus high
level of aggregation, rendering the particles failed to deposit
in the lower stages.
The siRNA formulation behaved somewhat differently to its
DNA counterpart. Overall, the siRNA powder formulation ex-
hibited a larger particle size, appeared to be more porous and
less robust. The aerosol performance of the siRNA formula-
tion was also less satisfactory. Despite that both siRNA and
herring sperm DNA are double stranded nucleic acid mol-
ecules with comparable size, the siRNA has a specific sequence
and well-defined molecular weight while the herring sperm
contained a heterogeneous mixture of oligonucleotides of vari-
able size. This subtle difference may partly contribute to their
difference in the surface and structural characteristics and
hence their aerodynamic properties. While further investiga-
tion is required, herring sperm DNAmay not be an ideal nucleic
acid model for siRNA for the initial formulation optimisation.
Nevertheless, this proof-of-concept study is the first to report
the use of spray freeze drying technology to produce dry powder
formulation of naked siRNA with modest aerosol properties.
Importantly, the physical integrity of siRNA was successfully
preserved in the absence of delivery vectors. Since the aerosol
performance of a powder formulation is also affected by the
Fig. 4 – In vitro aerosolisation performance of spray freeze dried powder formulations of DNA evaluated by next generation
impactor (NGI). (A) The emitted fraction of powders prepared at different solute concentration; (B) The fine particle fraction
of powders prepared at different solute concentration; (C) The emitted fraction of powders prepared at different DNA
concentration; and (D) The fine particle fraction of powders prepared with different DNA concentration. Data was presented
as mean ± SD (n = 3). Significant differences were determined using one-way ANOVA analysis followed by Tukey’s post-hoc
test. *, ** and *** represents P < 0.05, P < 0.01 and P < 0.001 respectively.
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Fig. 5 – The integrity of siRNA after spray freeze drying. (A) Gel retardation assay of siRNA samples. Each well contained
1 µg of nucleic acids. Numbers to the left of the ladder refer to the size of nucleic acids (DNA in base pairs). The samples are:
(1) siRNA control; (2) sense strand of siRNA; (3) 5-S-2.00 before spray freeze drying; and (4) 5-S-2.00 after spray freeze
drying. (B) HPLC spectra of siRNA samples. Retention time of siRNA duplex and its sense strand was 7.1 min and 5.8 min,
respectively. Unformulated siRNA and its sense strand were included as controls at equal amount to the powder samples.
Fig. 6 – Scanning electron microscopy (SEM) images of siRNA spray freeze dried powder formulation prepared at 5% w/v
solute concentration 2% w/w siRNA (5-S-2.00). The images were taken at (A) 1000 × magnification (scale bar = 50 µm); and
(B) 100 × magnification (scale bar = 500 µm).
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design of inhaler, a careful selected inhaler device could improve
the delivery efficiency. Further formulation optimisation using
a design of experiment (DoE) approach will be carried out and
the biological activities of the powders will be evaluated in the
future using suitable in vivo models.
4. Conclusion
In this study, the use of spray freeze drying to prepare
inhaled dry powder of small nucleic acids was explored. By
manipulating formulation parameters such as solute concen-
tration and nucleic acid concentration, the physical properties
including the porosity, particle size and aerodynamic perfor-
mance could be controlled.The presence study has successfully
demonstrated that spray freeze drying can be used to produce
naked siRNA formulation with intact integrity. The siRNA
powder exhibited an excellent dispersibility with a modest
fine particle fraction. Further exploration of this technology
to optimise inhaled dry powder formulation of siRNA is
warranted.
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